NEW YORK — Becton Dickinson said on Tuesday that it has partnered with Pfizer and charitable foundation Wellcome to study the role of diagnostics in supporting antimicrobial stewardship practices.
According to BD, the partners will survey existing diagnostic practices to understand the benefits and gaps in diagnostic testing in antimicrobial resistance stewardship. Additional details of the alliance were not disclosed.
"Having the right diagnostic tools for the right contexts and ensuring their uptake is crucial to fight antimicrobial resistance and save modern medicine," Gemma Buckland-Merrett, drug resistant infections research lead at Wellcome, said in a statement. "We need to preserve and sustain the efficacy and longevity of existing antimicrobials and protect the effectiveness of future drugs. This collaboration will help address the challenge and contribute to better outcomes for patients, clinical practice, and health care."